- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07943273
Treatment Outcomes and Molecular Prognostic Factors in TP53 Mutated Myeloid Neoplasms
TP53-mutated myeloid neoplasms encompass biologically heterogeneous disorders with frequent cytogenetic abnormalities and poor outcomes. In myelodysplastic neoplasms, TP53 allelic state contributes to clinical phenotype and prognosis. In acute myeloid leukemia (AML) and myelodysplastic syndromes with excess blasts, molecular similarities support studying TP53-associated disease across conventional diagnostic boundaries, although pooling lower-risk and advanced diseases can introduce important clinical heterogeneity. Available therapies improve remission in some patients without reliably producing durable disease control. In a pooled analysis of poor-risk cytogenetic AML with TP53 mutations, azacitidine plus venetoclax increased remission compared with azacitidine alone without a corresponding improvement in survival. A recent molecular analysis of the pivotal CPX-351 trial found that benefit was concentrated in AML with myelodysplasia-related mutations rather than TP53-mutated AML. Allogeneic hematopoietic cell transplantation (HCT) can provide prolonged survival in selected patients, but its outcome depends on biological and clinical context. Retrospective transplant data support integrating VAF and cytogenetics, whereas biological-assignment data in MDS suggest that some patients with TP53 mutations benefit from transplantation. the investigators sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure. Our purpose was hypothesis generation rather than causal ranking of regimens or derivation of a validated transplant-selection rule.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Thomas CLUZEAU
- Telefonnummer: +33 0492039025
- E-post: cluzeau.t@chu-nice.fr
Studera Kontakt Backup
- Namn: Caroline Fileni
- E-post: fileni.c@chu-nice.fr
Studieorter
-
-
Alpes Maritimes
-
Nice, Alpes Maritimes, Frankrike, 06000
- CHU de Nice
-
Kontakt:
- Thomas CLUZEAU
- Telefonnummer: +33 0492039025
- E-post: cluzeau.t@chu-nice.fr
-
Kontakt:
- Caroline Fileni
- E-post: fileni.c@chu-nice.fr
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
TP53 mutated AML and HR-MDS patients
Beskrivning
Inclusion Criteria:
- TP53 mutated myeloid AML (> 20% blasts) or HR-SMD
- Age: Age ≥ 18 years
- Allo-HCT was permitted.
- Available NGS analysis at diagnosis
- TP53 VAF > 2%
- Myeloid sarcoma were permitted
- Patients received at least 1 treatment line
Exclusion Criteria:
- TP53 mutations class 1 or 2 or 3 (American College of Medical Genetic and Genomics
- Patients alive at the start of the study who did not receive study information or who objected to the collection of data
- TP53 CCUS or CHIP
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: RETROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
TP53 mutated myeloid neoplasms from Nice University Hospital
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
|
TP53 mutated myeloid neoplasms from Saint-Louis University Hospital
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
We sought to describe treatment patterns and outcomes in a pooled TP53-associated clinical cohort and to explore cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF. A secondary objective was to describe transplanted patients according to available pre-HCT TP53 VAF and to assess HCT as a time-dependent exposure |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Description of clinical outcomes according to treatment patterns
Tidsram: Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027
|
We sought to describe treatment patterns in fonction of outcomes in a pooled TP53-associated clinical cohort |
Time from first administration of induction chemotherapy to death from any cause, assessed up to 01/01/2027
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
HCT as a time-dependent exposure.
Tidsram: Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027
|
Description of transplanted patients to assess HCT as a time-dependent exposure. |
Time from date of diagnosis then HCT to date of relapse or death from any cause, assessed up to 01/01/2027
|
|
Pre-HCT TP53 variant allelic frequency (VAF)
Tidsram: Baseline
|
Variant allelic fraquency of TP53 at diagnosis |
Baseline
|
|
Molecular prognostic
Tidsram: Baseline
|
To explore survival impact of cytogenetic abnormalities, TP53 mutation burden, co-mutation presence, and VAF |
Baseline
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 26Hemato01
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .